Douglas P. Fine

1.5k total citations
32 papers, 1.2k citations indexed

About

Douglas P. Fine is a scholar working on Epidemiology, Immunology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Douglas P. Fine has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 11 papers in Immunology and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Douglas P. Fine's work include Pneumonia and Respiratory Infections (8 papers), Complement system in diseases (7 papers) and Viral Infections and Vectors (5 papers). Douglas P. Fine is often cited by papers focused on Pneumonia and Respiratory Infections (8 papers), Complement system in diseases (7 papers) and Viral Infections and Vectors (5 papers). Douglas P. Fine collaborates with scholars based in United States. Douglas P. Fine's co-authors include Daniel G. Colley, John S. Sergent, Roger M. Des Prez, Samuel R. Marney, Richard D. Buchanan, H G Muchmore, J. C. Guckian, Daniel J. Sexton, Leonard N. Slater and Ronald A. Greenfield and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Immunology and Clinical Infectious Diseases.

In The Last Decade

Douglas P. Fine

31 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas P. Fine United States 18 368 356 307 280 211 32 1.2k
J M Orenstein United States 15 331 0.9× 278 0.8× 359 1.2× 240 0.9× 153 0.7× 18 1.3k
George W. Jordan United States 21 824 2.2× 339 1.0× 476 1.6× 162 0.6× 111 0.5× 47 1.8k
Anthony M. Smithyman United Kingdom 13 212 0.6× 152 0.4× 321 1.0× 124 0.4× 530 2.5× 28 1.5k
Finn T. Black Denmark 21 543 1.5× 219 0.6× 260 0.8× 338 1.2× 155 0.7× 58 1.7k
A.J.L. Weersink Netherlands 17 433 1.2× 356 1.0× 270 0.9× 141 0.5× 123 0.6× 36 1.3k
G. Cozon France 20 462 1.3× 604 1.7× 489 1.6× 462 1.6× 172 0.8× 57 1.8k
Joop Schellekens Netherlands 19 784 2.1× 400 1.1× 149 0.5× 154 0.6× 223 1.1× 24 1.6k
Warren C. Eveland United States 14 270 0.7× 172 0.5× 110 0.4× 85 0.3× 120 0.6× 42 997
K Varkila Finland 11 348 0.9× 172 0.5× 811 2.6× 92 0.3× 332 1.6× 17 1.7k
Robert E. Van Scoy United States 19 617 1.7× 391 1.1× 254 0.8× 54 0.2× 119 0.6× 48 1.5k

Countries citing papers authored by Douglas P. Fine

Since Specialization
Citations

This map shows the geographic impact of Douglas P. Fine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas P. Fine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas P. Fine more than expected).

Fields of papers citing papers by Douglas P. Fine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas P. Fine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas P. Fine. The network helps show where Douglas P. Fine may publish in the future.

Co-authorship network of co-authors of Douglas P. Fine

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas P. Fine. A scholar is included among the top collaborators of Douglas P. Fine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas P. Fine. Douglas P. Fine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fine, Douglas P.. (2018). Complement and Infectious Diseases.
2.
Sivaram, Chittur A., et al.. (1997). Introducing case management to a general medicine ward team of a teaching hospital. Academic Medicine. 72(6). 555–7. 7 indexed citations
3.
Huycke, Mark M., et al.. (1994). Rhodococcus equi Infections of Humans. Medicine. 73(3). 119–132. 126 indexed citations
4.
Istre, Gregory R., et al.. (1993). Invasive Pneumococcal Disease in Central Oklahoma: Emergence of High-Level Penicillin Resistance and Multiple Antibiotic Resistance. The Journal of Infectious Diseases. 168(6). 1532–1536. 54 indexed citations
5.
Kuhls, T L, et al.. (1992). Relapsing Pneumococcal Bacteremia in Immunocompromised Patients. Clinical Infectious Diseases. 14(5). 1050–1054. 17 indexed citations
6.
Fine, Douglas P., et al.. (1989). Genetic Analysis of Streptococcus pneumoniae Serotypes with the Use of DNA Fingerprinting. The Journal of Infectious Diseases. 160(1). 76–82. 21 indexed citations
7.
Grant, J. A., et al.. (1985). Familial exercise-induced anaphylaxis.. PubMed. 54(1). 35–8. 26 indexed citations
8.
Fine, Douglas P., et al.. (1983). Meningococcal meningitis in a woman with inherited deficiency of the ninth component of complement. Clinical Immunology and Immunopathology. 28(3). 413–417. 17 indexed citations
9.
Harper, Barbara, Douglas P. Fine, J. C. Guckian, & Tito Cavallo. (1981). Trypan blue inhibition of complement receptor function on various cells.. PubMed Central. 42(1). 61–6. 7 indexed citations
10.
Guckian, J. C., Tito Cavallo, & Douglas P. Fine. (1981). Opsonization of pneumococci. II. Metabolic effects of a "third" human serum activity that mediates intracellular killing.. The Journal of Immunology. 127(4). 1666–1670. 5 indexed citations
11.
Guckian, J. C., Gordon D. Christensen, Jo Ellen Schweinle, & Douglas P. Fine. (1981). Opsonization of pneumococci. I. Heat-labile serum activity other than complement is required for killing by human polymorphonuclear leukocytes.. The Journal of Immunology. 127(4). 1659–1665. 11 indexed citations
12.
Fine, Douglas P., et al.. (1980). Complement-independent Adherence of Escherichia coli to Complement Receptors In Vitro. Journal of Clinical Investigation. 66(3). 465–472. 6 indexed citations
13.
Guckian, J. C., Gordon D. Christensen, & Douglas P. Fine. (1980). The Role of Opsonins in Recovery from Experimental Pneumococcal Pneumonia. The Journal of Infectious Diseases. 142(2). 175–190. 42 indexed citations
14.
Guckian, J. C., Wayne Christensen, & Douglas P. Fine. (1978). Trypan Blue Inhibits Complement-Mediated Phagocytosis by Human Polymorphonuclear Leukocytes. The Journal of Immunology. 120(5). 1580–1586. 25 indexed citations
15.
Fine, Douglas P.. (1978). Coagulation and Complement Studies in Rocky Mountain Spotted Fever. Archives of Internal Medicine. 138(5). 735–735. 9 indexed citations
16.
Mosher, Deane F., et al.. (1977). Studies of the Coagulation and Complement Systems during Experimental Rocky Mountain Spotted Fever in Rhesus Monkeys. The Journal of Infectious Diseases. 135(6). 985–989. 9 indexed citations
17.
Hawley, H. Bradford, Tadataka Yamada, Deane F. Mosher, Douglas P. Fine, & Richard F. Berendt. (1977). Disseminated Intravascular Coagulopathy during ExperimentalPneumococcal Sepsis: Studiesin Normal and Asplenic Rhesus Monkeys. Journal of Medical Primatology. 6(4). 203–218. 6 indexed citations
18.
Fine, Douglas P., Richard D. Buchanan, & Daniel G. Colley. (1973). Schistosoma mansoni infection in mice depleted of thymus-dependent lymphocytes. I. Eosinophilia and immunologic responses to a schistosomal egg preparation.. PubMed. 71(2). 193–206. 47 indexed citations
19.
Fine, Douglas P., Samuel R. Marney, Daniel G. Colley, John S. Sergent, & Roger M. Des Prez. (1972). C3 Shunt Activation in Human Serum Chelated with EGTA. The Journal of Immunology. 109(4). 807–809. 284 indexed citations
20.
Fine, Douglas P., et al.. (1967). Intra-arterial infusion of dextran. Journal of Thoracic and Cardiovascular Surgery. 53(4). 496–499. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J M Orenstein Breakdown of academic impact, for papers by George W. Jordan Breakdown of academic impact, for papers by Anthony M. Smithyman Breakdown of academic impact, for papers by Finn T. Black Breakdown of academic impact, for papers by A.J.L. Weersink Breakdown of academic impact, for papers by G. Cozon Breakdown of academic impact, for papers by Joop Schellekens Breakdown of academic impact, for papers by Warren C. Eveland Breakdown of academic impact, for papers by K Varkila Breakdown of academic impact, for papers by Robert E. Van Scoy
Rankless by CCL
2026